抗神经生长因子（NGF）临床试验中的影像学现状。 - Suppr

Suppr

超能文献

The current status of imaging in anti-NGF clinical trials.

作者信息

Miller C G, Guermazi A, Roemer F

机构信息

Medical Affairs, BioClinica, Newtown, PA, USA.

Quantitative Imaging Center (QIC), Department of Radiology, Boston University School of Medicine, Boston, MA, USA.

出版信息

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002.

DOI:10.1016/j.joca.2014.09.002

PMID:25527218

Abstract

摘要

相似文献

The current status of imaging in anti-NGF clinical trials.抗神经生长因子（NGF）临床试验中的影像学现状。

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002.

Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies.抗神经生长因子（NGF）研究中潜在关节不良事件的入选资格及研究期间安全性的影像学图谱。

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S1-2. doi: 10.1016/j.joca.2014.08.014.

Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2).抗神经生长因子（NGF）研究中潜在髋关节不良事件的入选资格及研究期间安全性影像学图谱（第2部分）

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S43-58. doi: 10.1016/j.joca.2014.09.014.

Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1).抗神经生长因子（NGF）研究中潜在膝关节不良事件的入选资格及研究期间安全性影像学图谱（第1部分）

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S22-42. doi: 10.1016/j.joca.2014.09.015.

Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3).抗神经生长因子（NGF）研究中潜在肩部不良事件的入选资格及研究期间安全性的影像学图谱（第3部分）

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S59-68. doi: 10.1016/j.joca.2014.09.018.

Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.抗神经生长因子单克隆抗体随机对照试验中与关节相关的严重不良事件。

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S18-21. doi: 10.1016/j.joca.2014.10.005.

Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.用于治疗骨关节炎疼痛的神经生长因子抗体的现状

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):85-87. Epub 2017 Sep 28.

Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.单剂量抗神经生长因子抗体对骨关节炎大鼠模型运动时疼痛的长期镇痛作用，且对关节水肿和损伤无明显抑制作用。

Osteoarthritis Cartilage. 2015 Jun;23(6):925-32. doi: 10.1016/j.joca.2015.02.002. Epub 2015 Feb 9.

Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?神经生长因子阻断用于骨关节炎疼痛管理：我们能从临床试验和临床前模型中学到什么？

Curr Opin Rheumatol. 2017 Jan;29(1):110-118. doi: 10.1097/BOR.0000000000000354.

[The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].[创新与风险之间的微妙界限：抗神经生长因子会是未来的止痛药物吗？]

Schmerz. 2010 Dec;24(6):559-60. doi: 10.1007/s00482-010-0993-0.

引用本文的文献

Influence of Inflammation, Gut Microbiota, and Stress on Cognition and Oral Health Therapies.炎症、肠道微生物群和应激对认知及口腔健康治疗的影响。

Curr Alzheimer Res. 2025 Apr 11. doi: 10.2174/0115672050361661250327061024.

Role of imaging for eligibility and safety of a-NGF clinical trials.影像学在α-神经生长因子临床试验的入选资格及安全性评估中的作用。

Ther Adv Musculoskelet Dis. 2023 May 29;15:1759720X231171768. doi: 10.1177/1759720X231171768. eCollection 2023.

Retrograde nerve growth factor signaling modulates tooth mechanical hyperalgesia induced by orthodontic tooth movement via acid-sensing ion channel 3.逆行神经生长因子信号通过酸感应离子通道 3 调节正畸牙齿移动引起的牙齿机械性痛觉过敏。

Int J Oral Sci. 2021 Jun 4;13(1):18. doi: 10.1038/s41368-021-00124-6.

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.皮下注射替扎尼定治疗骨关节炎的一般安全性和耐受性：三项随机、安慰剂对照试验的汇总分析。

Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.替扎尼布治疗慢性腰痛：一项疗效和安全性的随机、双盲、安慰剂和阳性对照 3 期研究。

Pain. 2020 Sep 1;161(9):2068-2078. doi: 10.1097/j.pain.0000000000001928.

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.皮下注射替扎尼定治疗髋或膝关节骨关节炎：一项 24 周随机 III 期研究的疗效和安全性结果及 24 周随访期。

Ann Rheum Dis. 2020 Jun;79(6):800-810. doi: 10.1136/annrheumdis-2019-216296. Epub 2020 Mar 31.

Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.替扎尼布治疗髋关节或膝关节骨关节炎患者的关节疼痛、身体功能和患者整体评估的疗效：一项随机临床试验。

JAMA. 2019 Jul 2;322(1):37-48. doi: 10.1001/jama.2019.8044.

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety.神经生长因子抗体治疗骨关节炎疼痛和慢性腰痛：疗效和安全性背景下的作用机制。

Pain. 2019 Oct;160(10):2210-2220. doi: 10.1097/j.pain.0000000000001625.

Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models.骨关节炎疼痛的机制。人体研究与实验模型

Front Mol Neurosci. 2017 Nov 3;10:349. doi: 10.3389/fnmol.2017.00349. eCollection 2017.

Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?神经生长因子拮抗剂：单克隆抗体的未来是否变得更加清晰？

Drugs. 2017 Sep;77(13):1377-1387. doi: 10.1007/s40265-017-0781-6.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验